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Abstract 
Aims: Adverse-effects of psychological therapies are rarely recorded or considered. 
Sleep Restriction Therapy (SRT), an effective component of cognitive-behavioral 
therapy for insomnia, limits time-in-bed and may result in reduced total sleep time. 
Clinical evidence suggests that daytime impairment may be experienced by patients 
in the acute treatment period, yet there has been little systematic study of this 
possibility. Here, we investigated whether SRT is associated with reduced total sleep 
time, increased daytime somnolence and impaired vigilance. 
Design: Within-subjects, repeated measures treatment investigation with the addition 
of a matched good sleeper control group to permit between-group comparisons on 
performance measures. 
Setting: Sleep Research Laboratory 
Participants: Sixteen patients [10 female, Mean Age = 47.1 (10.8) yrs] with well-
defined psychophysiological insomnia (PI) and an age and gender-matched control 
group of good sleepers [GS, n=15; 10 female, mean age = 47.1 (10.5) yrs].   
Interventions: Patients were treated with single component SRT over a 4-week 
protocol, comprising one main session for treatment delivery and weekly sleep 
window titration (weeks 1-4). Patients slept in the laboratory for two nights prior to 
treatment initiation and for three nights (SRT night 1, 8, 22) during the acute 
interventional phase. In addition, those with PI completed the psychomotor vigilance 
task (PVT) at seven defined time-points [day 0 (baseline), day 1,7,8,21,22 (acute 
treatment) and day 84 (3 months)]. The Epworth Sleepiness Scale (ESS) was 
completed at baseline, weeks 1-4, and at three months. Matched good sleepers 
completed the PVT at one single time-point to permit baseline performance 
comparisons with patients.       
Measurement and results: Subjective sleep outcomes and global insomnia severity 
significantly improved pre-to-post SRT. There was, however, a decrease in PSG-
defined total sleep time during acute implementation of SRT, by an average of 91 
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minutes on night 1, 78 minutes on night 8, and 69 minutes on night 22, relative to 
baseline (p’s<.001; effect size range=1.60-1.80). During SRT, PVT lapses were 
significantly increased from baseline (at 3/5 assessment points, all p<.05; effect size 
range=.69-.77), returning to baseline levels by three months (p=.43). A similar pattern 
was observed for RT, with RTs slowing during acute treatment (at 4/5 assessment 
points, all p<.05; effect size range=.57-.89) and returning to pre-treatment levels at 
three months (p=.88). While patients did not differ from good sleepers at baseline 
with respect to PVT performance (p’s<.20), between-group differences began to 
emerge during SRT, with patients showing relative impairment. Objective measures 
were paralleled by significant elevations in subjective daytime sleepiness at weeks 1, 
2, and 3 (relative to baseline; all p<.05); by three months, sleepiness had returned to 
baseline (normative) levels (p=.65).   
Conclusion: For the first time we show that acute SRT is associated with reduced 
total sleep time, increased daytime sleepiness and objective performance 
impairment. Our data have important implications for implementation guidelines 
around the safe and effective delivery of CBT-I.     
Keywords: insomnia; CBT; sleep restriction therapy; vigilance; adverse effects; 
sleepiness 
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Introduction 
Cognitive-Behavioral Therapy for insomnia (CBT-I) is commonly regarded as the 
treatment of first choice for persistent insomnia disorder.1-3 CBT-I has been shown to 
be as effective as pharmacotherapy in the short-term but, in contrast to 
pharmacotherapy, leads to durable improvements in sleep (for up to 2 years post-
intervention).4 One of the frequently-cited advantages of CBT-I, and non-
pharmacological approaches in general, is the absence of, or potential for treatment-
related adverse effects.5,6 This is in contrast to pharmacotherapy where, for example, 
negative short- and long-term effects of sedative hypnotics have been well- 
described.7-10 Indeed, adverse effects are routinely assessed in randomised, 
placebo-controlled clinical trials of hypnotics and guide regulatory approval.11
Somewhat surprisingly, adverse-effects are almost never systematically recorded 
and/or reported in trials of psychological/behavioral treatments.5,12-14  
Sleep Restriction Therapy (SRT), a standard behavioral strategy used within multi-
component CBT-I2 and as a stand-alone intervention,6,15,16 involves restricting a 
patient’s time-in-bed (sleep window) to match their average (self-report) total sleep 
duration. The sleep window is then titrated, weekly, based on sleep efficiency (the 
proportion of time-in-bed spent asleep), in order to arrive at the patient’s core sleep 
requirement. Decreasing the opportunity to sleep over successive nights, it is argued, 
builds homeostatic sleep pressure, stabilises circadian control of sleep and 
wakefulness, and dampens pre-sleep cognitive and physiological (hyper)arousal, 
leading to shorter sleep latencies and more consolidated, uninterrupted sleep.6,17-20 
CBT-I practitioners often advise patients that, because of the reduced opportunity for 
night-time sleep, coupled with ‘prohibition’ of daytime napping, increased sleepiness 
may emerge during the initial phases of SRT implementation, resulting in a transient 
worsening of daytime functioning.18,21 Magnitude of time-in-bed restriction may also 
be affected by the well-established objective-subjective sleep discrepancies, known 
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to characterise some patients with insomnia.22-24 That is, patients may be assigned 
time-in-bed prescriptions that are significantly lower than pre-treatment objective 
sleep, leading to marked sleep loss over several weeks.6 Patients are, therefore, 
advised not to drive or operate heavy machinery if they feel excessively sleepy.18,21
Whilst these guidelines have evolved from clinical experience, there has been little 
systematic investigation of the nature or magnitude of CBT-I-induced daytime 
sleepiness and impairment. When investigating the utility of modafinil as an adjunct 
to CBT-I, Perlis and colleagues25 showed that those receiving CBT+placebo (n=10) 
reported increased Epworth Sleepiness Scale (ESS) scores one week post-SRT 
delivery. In contrast, both the therapeutic arm (CBT+modafinil) and additional control 
group (modafinil+contact) did not exhibit such a marked increase in ESS scores. Kyle 
et al.6 conducted the first in-depth examination of single-component SRT. A mixed-
methods approach was applied; involving questionnaire-based measures, semi-
structured interviews and real-time audio-diaries to probe the patient experience of 
treatment. During acute implementation of SRT, patients subjectively reported 
problems with excessive daytime sleepiness, which negatively affected daytime 
functioning beyond pre-treatment levels. Of note, over one-third of the audio-diary 
sub-sample complained, during real-time recordings, that driving was adversely 
affected [e.g.: ‘‘Woke up bright and breezy, half six, Tuesday morning, raring to go, 
got into the car. . . and within twenty minutes I was absolutely exhausted, so bad that 
I swear I was nearly falling asleep all the way to work. It was torture, I was cross-
eyed, eyes drooping, driving’’; ‘‘driving was a nightmare, and I’ve never ever had an 
issue with driving before’’; “I felt, really, I was a danger on the road” (Kyle et al.6; 
p741-742)]. Despite these acute difficulties, patients responded well to treatment, 
evidencing robust improvements in sleep and daytime functioning at three months 
follow-up. Recently, Miller et al. (in press) complemented these qualitative findings 
using ecological momentary assessment. The authors reported that point-in-time 
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assessments of ‘sleepiness/fatigue’ increased during week 1 of SRT, while ‘positive 
mood’ and ‘alert cognition’ decreased, relative to baseline.    
To date, no study has profiled whether subjective reports of treatment-related 
dysfunction are reflected in objective performance impairments. Moreover, it is 
unclear to what extent sleep is actually restricted during SRT and whether this is 
associated with elevated daytime sleepiness, measured with a validated instrument. 
Information on the magnitude and time-course of sleep loss, daytime sleepiness and 
performance impairment may have important implications for the future refinement, 
delivery and safe dissemination of CBT-I.  
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Method 
In the present study, 16 patients with psychophysiological insomnia took part in brief 
SRT. In order to profile changes in sleep time and objective performance, patients 
slept in the lab on five occasions (2 x baseline, 3 x during acute treatment) and 
completed a psychomotor vigilance task (PVT) at 7 defined time-points. The Epworth 
Sleepiness Scale (ESS) was also completed on a weekly basis (baseline, weeks 1-4 
and at 3 months) to index changes in daytime somnolence (see Figure 1 for 
schematic description of protocol). A control group of good sleepers (n=15) was 
recruited in order to examine baseline differences in PVT performance. 
We hypothesised that acute implementation of SRT would lead to reduced total sleep 
time which would be accompanied by impairments in vigilance (lapses and RT) and 
increased daytime sleepiness.   
Sample 
Sixteen thoroughly-screened patients with psychophysiological insomnia were 
recruited to take part in sleep restriction therapy for insomnia disorder. Individuals 
initially responded to media adverts looking for poor sleepers to sleep for two nights 
in the sleep laboratory, as part of a study into sleep-related attentional bias (grant # 
R01MH077901). This was a non-interventional study, but on completion of the 
overnight protocol (see below for details), those without evidence of occult sleep 
disorder pathology were invited to take part in the present treatment study, using 
SRT. A group of healthy age- and gender-matched good sleepers (n=15) was 
recruited for comparative purposes. 
Assessments
Sleep status: PI patients received a telephone interview by an expert in behavioral 
sleep medicine to assess the absence of co-morbidities and medication-use, as well 
8 
8 
as the presence of insomnia, defined as satisfying the following criteria for subjective 
sleep impairment: 
• report of sleep disturbance for at least 3 nights per week for at least 6 months 
• sleep onset latency (SOL) and/or wake-time after sleep-onset (WASO) > 30 
minutes 
• total sleep time < 6 hrs 
• sleep efficiency < 85%   
• daytime impairment attributed to disturbed sleep 
• Insomnia Severity Index score ≥ 15 
The phone interview was based on Morin & Espie21 and supplemented with a sleep 
disorders screening questionnaire.26 Those deemed eligible were invited to attend a 
screening day, involving a thorough sleep and psychiatric interview (Mini-
international Neuropsychiatric Interview; MINI27) with a licensed clinical psychologist 
trained in behavioral sleep medicine, and a medical assessment (ECG, blood 
chemistries, medical history, and drug screen) by a certified physician. Patients 
meeting Research Diagnostic Criteria for PI28, and who met all other 
inclusion/exclusion criteria, subsequently slept for two consecutive nights at the 
University of Glasgow Sleep Centre where they underwent polysomnographic (PSG) 
assessment (see below). 
Good sleepers received the same phone interview to assess inclusion/exclusion 
criteria, defined as the absence of sleep, psychiatric or (unstable) medical disorder, 
and the endorsement of good quality, restorative sleep, in addition to the following: 
• sleep onset latency (SOL) and wake-time after sleep-onset (WASO) < 15 
minutes 
• number of night-time awakenings ≤ 2 
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• total sleep time > 6 hrs 
• sleep efficiency > 85% 
• stable sleep period between 22:00 and 08:00   
All study participants completed a 7-day sleep diary (based on Morin & Espie21) to 
assess sleep continuity and quality and help rule out circadian phase disturbance. 
Patients completed sleep diaries for 6 weeks in total (baseline, treatment weeks 1-4 
and at 3 months). Participants also completed the Hospital Anxiety and Depression 
Scale (HADS30), supplementing the psychiatric screening interview and helping to 
rule out clinical-level anxiety/affective disorders. Patients completed the Insomnia 
Severity Index (ISI31), a sensitive measure of insomnia severity, at baseline, 4 weeks 
(post-treatment) and 3 months. Finally, patients completed the Epworth Sleepiness 
Scale (ESS32) at six time-points (baseline, weeks 1-4, and 3 months). The standard 
ESS does not include a specified time-frame and thus for the purpose of the present 
study, modifications were made so that patients completed the ESS with reference to 
“in the last week…”, permitting assessment of weekly sleepiness levels.     
It should be noted that matching between patients and controls was initiated on a 
subject-by-subject basis, with each patient matched with a corresponding good 
sleeper in terms of gender and age ± 2 yrs. Successful one-to-one matching was 
achieved for 14/16 patients.  
Polysomnography (PSG): A standard PSG montage was used, involving 
electroencephalographic [EEG: Fp1 (neutral), C3, P3 (reference), O1, Fpz, Fz, Cz, 
Pz, Oz, F4, C4], electrooculographic (EOG: horizontal and vertical) and 
electromyographic (submental) recordings. On night 1 of the baseline phase, all 
participants were screened for sleep-disordered breathing and periodic limb 
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movements through monitoring of abdominal and thoracic effort, nasal airflow, 
oximetry, and bilateral tibialis anterior EMG. Sleep was recorded on a lifelines 
trackitTM ambulatory recorder and scored visually by two experienced scorers (> 90% 
inter-scorer reliability) according to criteria by Rechtschaffen and Kales.29 For study 
inclusion, patients were required to have an Apnea Hypopnea Index (AHI) and 
Periodic Limb Movements of Sleep (PLMS) arousal index < 10. This initial night 
served as screening and adaptation to the sleep environment, while night 2 of the 
baseline phase was used as a comparator to index change during SRT. During 
baseline PSG assessment, patients implemented normal, ‘at-home’ bed and rise-
times (guided by sleep diary records).  
For the SRT intervention, patients slept in the sleep lab on three further nights (SRT 
nights 1, 8 and 22; see Figure 1) where sleep parameters were recorded (EEG, 
EMG, EOG) during implementation of a prescribed sleep window (based on sleep 
diary reports of total sleep time; see details of SRT intervention below). For the 
purpose of the present study, PSG-defined total sleep time (TST) was the only 
selected variable of interest, to index magnitude of sleep reduction between baseline 
and SRT nights. Future reports will focus on changes in objective sleep continuity 
parameters, as well as sleep macro and micro architecture, in relation to treatment 
response.    
Psychomotor vigilance task (PVT): The PVT is a frequently-used task in sleep 
research to assess the impact of sleep restriction, total sleep deprivation or altered 
sleep timing on basic vigilant attention. Evidence also exists that PVT metrics relate 
to driving simulator performance during sleep deprivation33 and that PVT 
performance is reliable across repeated administrations.34 The version of the PVT 
used in the present study has been applied in studies of insomnia and sleep 
perturbation.35,36  In the task, participants are asked to respond with a left mouse 
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click, as quickly as possible, to the presence of an asterisk located in the centre of 
the computer screen. Interval-onset for asterisks varied between 1 and 10 seconds in 
duration and there were 110 experimental trials. Participants completed five practice 
trials at the beginning of the session to aid task familiarity. The PVT was 
programmed in E-prime (http://www.pstnet.com/eprime.cfm) and completed on a Dell 
laptop, at a viewing distance of 40 cm. Task duration was approximately 13 minutes. 
Testing took place at 6pm. The following PVT metrics37 were analysed: (1) attentional 
‘lapses’ (defined as RTs > 500 msec); and (2) 1/mean RT (per trial).  
Intervention 
The SRT intervention involved one main session for delivery of treatment rationale 
and instructions, and four further brief, in-person or telephone interactions to titrate 
sleep efficiency (see Figure 1). Treatment was delivered by experts in behavioral 
sleep medicine via power-point slides to two patients at a time, and covered SRT 
rationale, sleep window calculation, and trouble-shooting around potential 
implementation difficulties. The sleep window was initially calculated based on one 
week of baseline sleep diaries, with time-in-bed prescriptions reflecting average total 
sleep time. The sleep window was subsequently titrated each week according to the 
following guidelines: sleep efficiency < 85%, decrease by 15 minutes; sleep 
efficiency ≥ 85-89%, no change; and sleep efficiency ≥ 90%, increase by 15 
minutes.17 The minimum sleep window was set at 5hrs. For those patients where the 
sleep window was deemed too difficult, restrictive or impossible to adhere to, a 
compromise was established between therapist and the patient. No other 
components of CBT-I were addressed during the intervention.      
The study protocol was reviewed and approved by the West of Scotland NHS 
research ethics committee (protocol no. 10/SO701/85) 
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[Insert Figure 1] 
Analysis 
Group differences (patients versus good sleepers), with respect to demographic and 
sleep-related variables, were assessed using independent t-tests. Treatment-related 
change in subjective sleep-diary outcomes (sleep-onset latency [SOL], wake-time 
after sleep-onset [WASO], sleep efficiency [SE]) and insomnia severity (ISI) were 
assessed with repeated measures analysis of variance (ANOVA), across baseline, 
post-treatment (week 4) and three month follow-up. PSG-TST (mins), daytime 
sleepiness (ESS) and vigilance (lapses, RT) were similarly assessed with repeated 
measures ANOVA. Significant main effects were followed up using paired t-tests. 
PSG-TST was compared across four nights [baseline (night number 2), and 
treatment nights (1, 8, and 22)], vigilance across seven time-points [[day 0 (baseline), 
day 1,7,8,21,22 (acute treatment) and day 84 (3 months)] and sleepiness across six 
time-points [baseline, weeks 1-4, 3 month follow-up]; with comparisons focused on 
change from baseline assessments. Effect sizes (ES) for paired data were calculated 
as follows: [mean difference / standard deviation of difference]. All comparisons were 
two-sided, with p<.05 indicating statistical significance, but given the apriori nature of 
our directed hypotheses, p values and effect size data are also reported for p’s ≤.1.    
While the primary analyses of interest focussed on assessment of within-subject 
change for vigilance, sleepiness and PSG-TST, recruitment of a group of good 
sleepers also permitted between-group comparisons. Thus, for PVT performance 
(lapses and RT), exploratory comparisons between healthy controls and PI patients 
were conducted at baseline and during treatment assessments, using independent t-
tests (and effects quantified using Cohen’s d: (M1 – M2 / δ pooled).38  
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Results 
Sample 
Sixteen patients [10 female, Mean Age = 47.1 (10.8) yrs] initially enrolled in the study 
and completed session 1. One patient dropped out in the first week due to concerns 
about the impact of SRT on work functioning. The fifteen remaining participants 
completed the full protocol (five lab nights and seven neurocognitive assessments), 
including 12-week follow-up. Mean age of the remaining 15 patients was 47.2 yrs 
(SD=10.4) and 10 (66.6%) were female. The control group of good sleepers were 
identical in both age (47.1, SD=10.5) and gender (10 female [66.6%]). As expected, 
PI patients demonstrated significant sleep disturbance at baseline relative to good 
sleepers (see Table 1), and reported greater levels of anxiety and depression. Of 
note, and consistent with the diagnosis of PI, anxiety and depression scores were in 
the mild range and approximate those found in large non-clinical samples.39   
[Insert Table 1] 
Subjective sleep: manipulation check of the SRT protocol  
The average prescribed sleep window for the first week of therapy was 347.0 
minutes (SD=32.0), which increased by 15 minutes over the four week acute SRT 
phase (week 4 = 362.0 minutes, SD=33.0; see Figure 2). Sleep diary records of time-
in-bed decreased from a baseline of 483.2 minutes (SD=74.1) to 353.2 minutes 
(SD=36.1) during week 1, in line with prescribed sleep window times, indicating close 
adherence to the SRT protocol (see Figure 2). 
[Insert Figure 2] 
Insomnia severity (measured with the ISI) significantly reduced across assessment 
points [F(2,24)=85.07, p<.001), decreasing from 17.4 (SD=2.8) at baseline to 7.7 
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(SD=3.9) at four weeks (p<.001). Further reductions were observed between week 4 
and 3 months (5.08, SD=4.1; p=.004, and p<.001 for comparison with baseline). 
Subjective reports of SOL similarly changed over assessment period 
[F(1.04,11.39)=16.24, p=.002], reducing from 32.2 (SD=21.8) minutes at baseline to 
9.4 minutes (SD=5.4) at four weeks (p<.01) and remaining at this level (8.1, SD=5.2) 
at 3-months follow-up. Both WASO and sleep efficiency showed robust changes over 
time [WASO: F(1.04,11.41)=9.04, p=.011 and SE: F(1.07,11.75)=28.34, p<.001]. 
WASO significantly reduced from 66.8 (SD=60.7) minutes at baseline to 12.4 
minutes (SD=10.1; p=.01) at post-treatment, remaining at this level at three months 
(16.2 minutes, SD=16.7). Changes in WASO and SOL were reflected in improved 
sleep efficiency, increasing from 68.0% (SD=13.7) at baseline, to 90.7% (SD=4.4; 
p<.001) at 4 weeks, which was maintained at three months (91.3%, SD=4.8). Finally, 
subjective TST estimates showed fluctuation over assessment points [F(2,22)=13.04, 
p=.001]. While there was no change in TST between baseline and post-treatment 
(326.8, SD=61.1 vs. 334.9, SD=37.1; p=.50), by three months TST had improved by 
approximately 1 hour, to 383.2 mins (SD=49.3; p<.01 for baseline comparison).  
Psychomotor Vigilance Task (PVT) performance 
PVT performance was first compared across good sleepers (n=15) and PI patients 
(n=15; pre-treatment). Independent t-tests did not reveal any significant baseline 
group differences for number of attentional lapses [PI = 7.4 (SD=7.2) vs. GS = 7.2 
(SD=10.7); t=.49, p=.62] or 1/mean RT [PI = 2.87 (SD=.30) vs. GS = 3.03 (SD=.36); 
t=1.31, p=.20]. 
Changes in patient PVT performance across the treatment protocol [days 
0,1,7,8,21,22,84] were next examined with repeated-measures ANOVA. A main 
effect of time was observed for attentional lapses [F(6,84)=4.45, p=.001] and a 
significant quadratic trend [F(1,39)=30.52, p<.001; see Figure 3]. Relative to baseline 
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(day 0), number of lapses increased (non-significantly) at day 1 (p=.10; ES=.45) and 
7 (p=.075; ES=.50), and were significantly elevated at day 8 (p=.010; ES=.77), 21 
(p=.009; ES=.78) and 22 (p=.018; ES=.69) of SRT. By day 84 (three months), lapses 
returned to baseline levels (baseline = 7.4 vs. 3 months = 7.0; p=.43). Exploratory 
comparisons between the PI group (during SRT) and good sleepers, revealed the 
emergence of group differences at day 8 (p=.046; Cohen’s d=.76), and non-
significant trends for day 21 (p=.075; Cohen’s d=.68) and day 22 (p=.091; Cohen’s 
d=.64), with patients evidencing relative impairment. Patient performance at follow-up 
(day 84) did not differ from good sleepers (p=.99).     
Similar findings were observed for RT, reflected in a significant main effect of time 
[F(6,84)=3.11, p=.008], accompanied by a significant quadratic trend [F(1,14)=7.59, 
p=.015; see Figure 4]. Relative to baseline (day 0), patient RTs increased at day 1 
(p=.042; ES=.58), day 8 (p=.045; ES=.57), day 21 (p=.034; ES=.61) and day 22 
(p=.004; ES=.89). By day 84 (three months), RTs had returned to baseline levels 
(2.85, SD=.35 vs. 2.87, SD=.29; p=.78). Exploratory comparisons between the PI 
group (during SRT) and good sleepers, revealed the emergence of group differences 
at day 8 (p=.051; Cohen’s d=.74), day 21 (p=.029; Cohen’s d=.85) and day 22 
(p=.009; Cohen’s d=1.03), with patients evidencing relative impairment. Patient 
performance, at follow-up (day 84), did not differ from good sleepers (p=.20).     
[Insert Figures 3 & 4] 
Daytime Sleepiness 
Sleepiness evidenced a significant main effect [F(5,60)=7.26, p<.001] and a 
significant quadratic trend [F(1,12)=11.58, p=.005; see Figure 5]. ESS scores 
significantly increased from baseline to week 1 [4.95, SD=3.02 vs. 8.69, SD=4.96; 
p=.004, ES=.98], week 2 [9.08, SD=5.84; p=.006, ES=.92], and week 3 [7.85, 
16 
16 
SD=5.8; p=.035, ES=.66]. There were no significant differences between ESS scores 
at baseline and week 4 (6.85, SD=5.18; p=.112) or between baseline and week 12 
(3.80, SD=4.96, p=.652).   
[Insert Figure 5] 
PSG-defined Total Sleep Time (TST) 
We next assessed the magnitude of change in PSG-TST, from the baseline PSG 
night (pre-treatment) relative to SRT acute implementation, and the extent to which 
TST varied across the three SRT lab nights (nights 1, 8, and 22). There was a 
significant main effect of time [F(3,39)=27.03, p<.001; see Figure 6]. Baseline TST 
was 393.6 minutes (SD=43.0), which decreased by approximately 90 minutes on the 
first night of SRT (302.4, SD=53.0; p<.001, ES=1.62), remaining significantly reduced 
at night 8 (315.6, SD=26.7; p<.001, ES=1.80) and night 22 (324.6, SD=34.6; p<.001, 
ES=1.60). TST exhibited a trend towards improving between night 8 and 22 (by 
approximately 22 minutes; p=.052, ES=.57).      
[Insert Figure 6] 
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Discussion 
CBT-I is widely regarded as the most effective treatment option for chronic insomnia. 
Similar to psychological therapies in other fields, CBT-I is promoted as a safe and 
adverse-effect-free intervention. Our clinical and research experience suggests that 
CBT components, particularly SRT, may be associated with some negative effects, 
but examination and evidence is lacking.6,21 Understanding possible treatment-
related adverse effects has important implications for patient care. In the present 
study, we aimed to quantify the impact of SRT on objectively-defined vigilance, 
daytime sleepiness and objective total sleep time. 
The first thing to say is that SRT effectively improved the core symptoms of insomnia. 
That is, by week 4, diary ratings of SOL, WASO and SE had all improved relative to 
baseline (with corresponding large effects). Changes in sleep diary parameters were 
also reflected in reduced ratings of overall insomnia severity. These findings were 
maintained (or enhanced) at three months follow-up. Of course, our aim was not to 
test the effectiveness of SRT per se, but results from our (uncontrolled) work support 
the growing literature that SRT is an effective, single-component intervention.15,16
Furthermore, improvements in sleep, coupled with reductions in diary-reported TIB 
during SRT – almost overlapping with prescribed sleep window times – suggests that 
patients followed the protocol faithfully. 
Despite these post-treatment improvements in sleep continuity and insomnia 
severity, PVT performance was found to deteriorate during acute SRT 
implementation, reflected in a greater number of attentional lapses and slowed RT. 
To our knowledge, this is the first evidence that SRT (or any component of CBT-I) is 
associated with objective performance impairment. Performance was impaired on 3/5 
assessment points for attentional lapses and 4/5 assessment points for reaction time, 
relative to baseline (moderate-to-large effects). By 3 months, performance had 
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returned to baseline levels. Whilst patients did not differ from good sleepers at 
baseline, consistent with meta-analytic data,40 between-group effects started to 
emerge when SRT was initiated; with patients showing slowed RTs and increased 
lapses. That is, in this study sample and protocol, insomnia per se was not 
associated with impaired vigilance, but acute treatment was.  
Deterioration in PVT performance was paralleled by increased daytime sleepiness as 
reflected in ESS scores. Patients reported significantly elevated ESS scores during 
weeks 1-3 of treatment (moderate-to-large effects). By 3 months, however, and 
similar to PVT performance, ESS scores had returned to baseline levels. A reduction 
in total sleep time is the most intuitive explanation for degraded performance and 
increased sleepiness during treatment. Comparing PSG nights, we observed a large 
reduction in TST by approximately 91 minutes on SRT night 1, 78 minutes on night 8 
and 69 minutes on SRT night 22. Chronic sleep restriction protocols in healthy 
subjects, even with sleep curtailment of just 1.5 hours, reveal cumulative impairments 
in PVT performance over a 14-day period.41,42 Although we were not able to asses 
vigilance or objective sleep on a daily basis, it is interesting that performance 
appears to follow a relatively linear (cumulative) decline throughout the acute phase 
of SRT, with impairments tending to be most pronounced on days 8, 21 and 22. It is 
also clear that PSG-defined TST is relatively stable over the three assessment nights 
(increasing by 22 minutes from night 1 to night 22), and the prescribed sleep window 
was extended by just 15 minutes over the entire four week treatment protocol (see 
Figure 2). 
Our findings are difficult to compare with published literature because few studies 
have investigated the acute phase of insomnia treatment; instead, tending to focus 
on pre-to-post treatment outcomes. Previous work by our group6,20  and others17,25,43,44 
provide both systematic and clinical evidence of treatment-related difficulties, 
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including self-reported sleepiness, cognitive impairment and implementation 
challenges, but longitudinal tracking of sleep and functioning is lacking. Treatment 
studies that have used PSG to assess sleep outcomes, pre-to-post CBT-I, have not 
found convincing evidence of change in TST4 and, to our knowledge, no published 
study has examined the magnitude of TST/TIB reduction during acute 
implementation. However, inspection of published CBT-I trial data, where both 
objective (PSG) and subjective (sleep diary) baseline data are reported, indicates 
that TST discrepancies often range between 50 and 60 minutes45-47 (indeed, in one 
study, as high as 83 minutes)47; and it is well known that a general objective-
subjective sleep discrepancy exists in some patients with insomnia.23,24,48 This 
discrepancy has important implications for sleep window calculation and the degree 
to which patients may be sleep restricted during, and possibly after, CBT treatment 
monitoring.  
On this point, Morin and colleagues49 reported that PSG-defined TST was 
significantly reduced (moderate to large effect) in the CBT treatment arm at 6 weeks 
(post-treatment), and Buysse et al.50 reported significant reductions in actigraphy-
defined TST relative to an information-only control group after four weeks of brief 
behavioral therapy (SRT+Stimulus Control Therapy). Thus, it would appear that TST 
reduction during CBT-I is likely the norm, rather than the exception, but the field lacks 
consistent (week-by-week) process data to answer this question definitively. 
Crucially, TST appears to return to at least baseline levels during follow-up PSG 
assessments,46,47,49,51 suggesting that CBT exerts its therapeutic effect, at least in 
part, through correction or restoration of sleep-wake perception.45 Priming sleep 
pressure through TST reduction may also be necessary to overcome cognitive 
arousal and consolidate sleep,6,19,20,52 but these putative mechanistic routes require 
further experimental attention. Importantly, there exists the possibility that some 
patients - perhaps treatment non-responders - continue to implement SRT for a 
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prolonged period of time which, if associated with chronic sleep restriction, could 
have detrimental health effects.53    
Limitations 
Our findings must be interpreted within the context of several limitations. Principally, 
our sample size was small and we did not include an untreated (patient) control 
group. This limitation is partially mitigated through triangulation of methodologies 
(PSG, performance impairment, self-reported sleepiness), coupled with normalised 
trajectories of sleepiness and vigilance, at follow-up; giving us some confidence in 
our conclusions. Nevertheless, we cannot conclude with certainty that SRT was 
responsible for the observed effects. Recruitment of a group of untreated insomnia 
patients, a group receiving another CBT-I component or an inactive intervention 
should be considered in future research studies. We also realise that SRT is often 
introduced within the context of a full CBT-I package and so our results may not 
generalise to all CBT-based interventions. An important point to bear in mind is that 
SRT is commonly introduced in the second or third session of CBT-I protocols54-57 
and as such the sleep window may not be calculated based on pre-treatment diary 
values, but instead from sleep parameters measured during the first 2 weeks of CBT-
I. This would potentially lead to longer sleep window prescriptions, because sleep 
may already be improving, than if the sleep window were based on pre-treatment 
data. However, this remains an empirical question that could be addressed through 
re-analysis of existing datasets.  
A related point is that in-lab SRT, due to increased monitoring and strict scheduling 
of the sleep window, may have led to greater adherence and possibly enhanced 
impairment. In practice, it is likely that patients tend to modify the duration and timing 
of the sleep window (in the home environment) based on individual preferences and 
ability to function. Nevertheless, it is important to understand the full impact of SRT 
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when patients adhere faithfully to the prescribed programme. Convergence of diary-
recorded TIB and prescribed sleep window durations (see Figure 2), would support 
this conclusion.   
In the present study our intention was to isolate SRT, since this intervention has been 
found to be very effective (when used in single-component interventions), yet difficult 
to implement43 and our early work suggested the possibility of treatment-related 
impairment.6,20 It is worth pointing out however, that stimulus control therapy may 
also be associated with acute sleep loss, and possible impairment. Future work 
should attempt to characterise the magnitude and time-course of stimulus-control-
related impairment (in isolation) as well as in combination with SRT, since many 
programmes combine these two behavioral interventions.50,54-58   
Finally, because we did not assess performance beyond three weeks (or sleepiness 
beyond 4 weeks) we cannot determine exactly when vigilance started to normalise. 
From ESS data it would appear that, by week 4, sleepiness was beginning to 
weaken, but future work should profile daytime performance (including objective 
measures of sleep debt e.g. multiple sleep latency test) for several weeks beyond 
active treatment/monitoring.  
       
Clinical implications 
We think it reasonable, even mandatory, to reflect on what might be the clinical 
impact of our results. Assuming there is a “necessary pain to achieve gain” with SRT, 
clinicians should emphasise that CBT-I may negatively affect vigilance levels, and 
those that are identified as excessively sleepy, pre-treatment, or appear to report 
gross subjective-objective sleep discrepancies, should be assigned a more liberal 
sleep window. There currently exists variation in the minimum TIB sleep window 
used in SRT, as well as variation in TIB calculation and titration method.18 The field 
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should aim to reach a consensus on what is the recommended SRT protocol as well 
as any required modifications for specific populations (cancer, depression, bipolar 
disorder, co-morbid chronic pain).56,59 Consensus should be guided by experimental 
manipulations, which are needed to reveal treatment mechanisms6,20 and to provide 
empirical data on the ‘dose’ of sleep restriction required to bring about treatment 
response. Related to this, the suitability and feasibility of using objective measures to 
guide sleep-window generation and titration should also be considered.  
Finally, we realise that some labs and therapists set a minimum TIB as low as 4.5 
hours.17,59  Indeed, had we set this as our minimum TIB three participants would have 
been assigned a 4.5hr sleep window and another patient, 4.75 hrs. It remains 
possible, indeed likely, that minimum TIB as low as 4.5hrs may lead to impairment 
greater than that observed in the present study. Going forward, the standardisation of 
SRT procedures, often regarded as the most effective ingredient of CBT-I 
interventions, should be considered a research and clinical priority for BSM 
specialists.  
23 
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Table 1: Demographic and sleep characteristics for PI patients and GS controls. 
        
GS (n=15) PI (n=16)
      
Age (SD) 47.1 (10.5) 47.1 (10.8)
Gender % 
(F:M) 66.7/33.3 62.5/37.5
ISI - 17.8 (2.8)
HADS-A 2.1 (2.3) 6.4** (4.0) 
HADS-D 0.9 (1.6) 4.0** (2.2) 
SOL (mins) 7.1 (7.9) 38.8** (32.4)
WASO (mins) 6.8 (11.2) 62.6** (58.8)
No. Awak 1.2 (1.4) 2.1# (1.3)
TST (mins) 449.9 (41.7) 338.7**(57.4)
TIB (mins) 503.1 (51.0) 490.6 (66.8)
SE (%) 89.9 (6.3) 69.3** (12.3)
SQ (0-4) 3.3 (0.4)   1.7** (0.6) 
ISI=Insomnia Severity Index; HADS-A/D=Hospital Anxiety 
and Depression Scale; SOL=sleep-onset latency; 
WASO=wake-time after sleep-onset; TST=total sleep 
time; TIB=time-in-bed; SE=sleep efficiency; SQ=sleep 
quality 
**p<.01, #p<.10 for group comparison 
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          Figure 1: schematic presentation of study protocol. 
                                                        [sleep diaries completed throughout]
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Figure 2: Descriptive profiles of mean (SE) time-in-bed sleep window prescriptions 
(weeks 1-4) and sleep-diary reported time-in-bed (TIB) over the course of SRT 
protocol. 
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Figure 3: Mean (±SE) number of attentional lapses (RTs > 500 msec.) over the 
course of SRT treatment [**p≤.01, *p<.05 for comparison with baseline]. 
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Figure 4: PVT RT (1/mean RT ± SE) over the course of SRT treatment. Note, lower 
scores indicate a slowing in RT. [**p≤.01, *p<.05 for comparison with baseline]
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Figure 5: Mean (±SE) ESS scores throughout treatment weeks. [**p<.01, *p<.05 for 
comparison with baseline] 
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Figure 6: Mean (±SE) PSG-determined TST (mins) pre-treatment and during SRT. 
[**p<.001 for comparison with baseline] 
** ** **
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